Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Insider and Institutional Ownership
96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 6.8% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Apellis Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Apellis Pharmaceuticals | -34.97% | -103.11% | -28.96% |
| Aprea Therapeutics | -1,029.50% | -57.86% | -47.94% |
Analyst Recommendations
This is a breakdown of recent recommendations for Apellis Pharmaceuticals and Aprea Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apellis Pharmaceuticals | 0 | 8 | 10 | 1 | 2.63 |
| Aprea Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Apellis Pharmaceuticals currently has a consensus target price of $46.71, suggesting a potential upside of 79.64%. Aprea Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 520.00%. Given Aprea Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Apellis Pharmaceuticals.
Earnings & Valuation
This table compares Apellis Pharmaceuticals and Aprea Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apellis Pharmaceuticals | $396.59 million | 8.15 | -$528.63 million | ($2.03) | -12.81 |
| Aprea Therapeutics | $580,000.00 | 23.43 | -$14.29 million | ($2.81) | -0.89 |
Aprea Therapeutics has lower revenue, but higher earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Apellis Pharmaceuticals beats Aprea Therapeutics on 8 of the 15 factors compared between the two stocks.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
